VERU

MKT CAP:$37M

Veru Inc.

Market Cap

$37M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.40+$0.13 (+5.51%)

Apr 21, 2026

Company Details

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the...

CEO

Mitchell S. Steiner

IPO Date

Feb 11, 1999

Website

www.verupharma.com

Key Metrics TTM

Revenue

$247.1K

-98.3% YoY

Net Income

-$19M

EPS (Diluted)

-$1.21

Free Cash Flow

-$25M

Revenue / Share

$0.01

Gross Margin

-46.7%

Operating Margin

-8065.1%

Net Margin

-7736.3%

FCF Margin

-10070.1%

P/S

151.4x

P/E

—

Earnings Reports

Q2 2026

May 14, 2026

PENDING

Q1 2026

Feb 11, 2026

$0EPS -$0.26

FY 2025

Dec 17, 2025

$0-100.0%EPS -$1.07

Q4 2025

Dec 17, 2025

$247.1K-96.3%EPS $0.09

Q3 2025

Aug 12, 2025

$0-100.0%EPS -$0.50

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$13M	$11M	-$12M
Q3 22	$10M	$7M	-$22M
Q4 22	$3M	$505.4K	-$45M
Q1 23	$3M	$702.1K	-$37M
Q2 23	$7M	$4M	-$34M
Q3 23	$3M	$1M	$5M
Q4 23	$4M	$2M	-$12M
Q1 24	$2M	$1M	-$9M
Q2 24	$4M	$678.3K	-$10M
Q3 24	$4M	$1M	-$11M
Q4 24	$7M	$3M	-$8M
Q1 25	$0	-$64.9K	-$10M
Q2 25	$0	-$29.3K	-$8M
Q3 25	$0	-$29.3K	-$8M
Q4 25	$247.1K	-$28.6K	$1M
Q1 26	$0	-$28.2K	-$5M

Valuation

Quarter	P/S	P/E
Q2 22	0.6x	—
Q3 22	0.7x	—
Q4 22	1.0x	—
Q1 23	1.3x	—
Q2 23	1.8x	—
Q3 23	2.5x	—
Q4 23	2.3x	—
Q1 24	2.3x	—
Q2 24	2.8x	—
Q3 24	2.7x	—
Q4 24	2.2x	—
Q1 25	2.5x	—
Q2 25	3.5x	—
Q3 25	5.6x	—
Q4 25	151.4x	—
Q1 26	151.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	-$4M	-$4M
Q3 22	-$14M	-$14M
Q4 22	-$21M	-$21M
Q1 23	-$35M	-$35M
Q2 23	-$26M	-$26M
Q3 23	-$18M	-$18M
Q4 23	-$9M	-$10M
Q1 24	-$6M	-$6M
Q2 24	-$6M	-$6M
Q3 24	-$6M	-$6M
Q4 24	-$4M	-$4M
Q1 25	-$11M	-$11M
Q2 25	-$8M	-$8M
Q3 25	-$5M	-$5M
Q4 25	-$5M	-$5M
Q1 26	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q2 22	$185.2K
Q3 22	$96.8K
Q4 22	$148.8K
Q1 23	$285.6K
Q2 23	$141.6K
Q3 23	$25.7K
Q4 23	$212.9K
Q1 24	$0
Q2 24	$40.7K
Q3 24	$54.6K
Q4 24	$63.0K
Q1 25	$1.1K
Q2 25	$0
Q3 25	$0
Q4 25	$4
Q1 26	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	-2.3%	+67.4%
Q3 22	-45.6%	+53.1%
Q4 22	-83.5%	+169.8%
Q1 23	-82.3%	+110.0%
Q2 23	-49.4%	+65.4%
Q3 23	-65.2%	-104.8%
Q4 23	+49.2%	-66.6%
Q1 24	-14.6%	-72.6%
Q2 24	-37.2%	-65.8%
Q3 24	+18.3%	+1081.0%
Q4 24	+72.4%	-5.7%
Q1 25	-100.0%	-6.3%
Q2 25	-100.0%	-42.1%
Q3 25	-100.0%	-49.3%
Q4 25	-96.3%	-106.2%
Q1 26	—	-47.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$2M	16.3%
Q3 22	$3M	30.3%
Q4 22	$4M	167.1%
Q1 23	$5M	193.2%
Q2 23	$4M	58.3%
Q3 23	$5M	136.2%
Q4 23	$5M	121.3%
Q1 24	$3M	159.1%
Q2 24	$4M	87.9%
Q3 24	$3M	85.4%
Q4 24	$3M	48.5%
Q1 25	$3M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$2M	621.2%
Q1 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q2 22	$16M	—	$7M
Q3 22	$18M	—	$11M
Q4 22	$27M	—	$18M
Q1 23	$21M	—	$18M
Q2 23	$18M	—	$13M
Q3 23	$3M	—	$11M
Q4 23	$7M	$13M	—
Q1 24	$2M	—	$7M
Q2 24	$3M	—	$8M
Q3 24	$5M	—	$8M
Q4 24	$3M	—	$8M
Q1 25	$6M	—	$5M
Q2 25	$4M	—	$5M
Q3 25	$3M	—	$5M
Q4 25	$3M	$14M	—
Q1 26	$1M	$4M	—

Revenue by Geography

Quarter	Other Countries	U	Z	Mozambique	Other Geographical Areas	United States
Q2 22	$1M	$12M	—	—	—	—
Q3 22	$3M	$7M	—	—	—	—
Q4 22	$2M	$650.0K	—	—	—	—
Q2 23	$470.3K	$5M	$1M	—	—	—
Q3 23	$1M	$1M	$612.0K	—	—	—
Q3 24	—	—	—	$1M	$2M	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$112M	$0	$112M
Q3 22	$101M	$0	$101M
Q4 22	$80M	$0	$80M
Q1 23	$47M	$0	$47M
Q2 23	$23M	$0	$23M
Q3 23	$16M	$0	$16M
Q4 23	$10M	$0	$10M
Q1 24	$41M	$0	$41M
Q2 24	$35M	$0	$35M
Q3 24	$29M	$0	$29M
Q4 24	$25M	$0	$25M
Q1 25	$27M	$0	$27M
Q2 25	$20M	$0	$20M
Q3 25	$15M	$0	$15M
Q4 25	$16M	$3M	$18M
Q1 26	$33M	$2M	$35M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	8M	+0.0%	+6.5%
Q3 22	8M	+0.0%	+0.5%
Q4 22	8M	+0.3%	+0.5%
Q1 23	8M	+0.3%	+0.7%
Q2 23	8M	+0.3%	+1.0%
Q3 23	9M	+9.2%	+10.2%
Q4 23	9M	+4.0%	+14.3%
Q1 24	10M	+9.6%	+24.9%
Q2 24	15M	+45.5%	+81.1%
Q3 24	15M	+0.0%	+65.8%
Q4 24	15M	+0.0%	+59.5%
Q1 25	15M	0.0%	+45.5%
Q2 25	15M	+0.0%	+0.0%
Q3 25	15M	+0.1%	+0.1%
Q4 25	15M	-0.1%	+0.1%
Q1 26	20M	+38.6%	+38.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$51.7K	252
Q3 22	$38.1K	252
Q4 22	$11.1K	233
Q1 23	$10.8K	233
Q2 23	$28.3K	233
Q3 23	$14.3K	233
Q4 23	$20.4K	189
Q1 24	$11.3K	189
Q2 24	$21.9K	189
Q3 24	$20.9K	189
Q4 24	$31.7K	210
Q1 25	$0	210
Q2 25	$0	210
Q3 25	$0	210
Q4 25	$12.4K	20
Q1 26	$0	20

Revenue / Employee